Research programme: glutamate modulators - Biohaven Pharmaceutical Holding Company

Drug Profile

Research programme: glutamate modulators - Biohaven Pharmaceutical Holding Company

Alternative Names: Glutamatergic agents - Biohaven; Neuropsychiatric disorder therapeutics - Biohaven; Riluzole - Biohaven

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fox Chase Chemical Diversity Center; Yale University
  • Developer Biohaven Pharmaceutical Holding Company
  • Class Benzothiazoles; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Glutamate receptor antagonists; Glutamate-release-inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Mental disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for research development in Mental-disorders in USA
  • 01 Oct 2015 Biohaven and Fox Chase Chemical Diversity Center agree to develop glutamate modulators
  • 18 Aug 2015 Biohaven acquires Glutamate modulator prodrugs from ALS Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top